Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Chỉ hiển thị Multimedia

Osimertinib linked to cardiac events in NSCLC patients
26 Nov 2025
bởiStephen Padilla
Patients with non-small cell lung cancer (NSCLC) treated with osimertinib have a higher risk of QT prolongation, reduced ejection fraction, and high-grade cardiac failure than those who received placebo or other standard therapies, reports a study.
Osimertinib linked to cardiac events in NSCLC patients
26 Nov 2025
Tirzepatide trims risk of major adverse cardiovascular events
26 Nov 2025
bởiStephen Padilla
Treatment with tirzepatide 15 mg/week results in a 33-percent reduction in the risk of major adverse cardiovascular events (MACE), results of a meta-analysis have shown. Moreover, its efficacy is consistent across individuals with or without obesity.







